CD56+CD3- % is a specialized immunological parameter, playing a pivotal role in the field of clinical immunology and hematology. This parameter specifically refers to the percentage of cells in the blood that express the CD56 marker but lack the CD3 marker. CD56 is a surface protein typically found on natural killer (NK) cells, a type of white blood cell crucial for the innate immune response, particularly in fighting viral infections and in cancer surveillance. The absence of the CD3 marker, typically present on T cells, helps in distinguishing these NK cells from other lymphocytes.
The CD56+CD3- % measurement is critical in diagnosing and monitoring various hematological disorders and immune deficiencies. For instance, an elevated percentage of CD56+CD3- cells can be indicative of an active immune response or certain hematological malignancies, such as NK cell leukemia. Conversely, a decreased percentage might suggest an impaired immune system, often seen in conditions like HIV/AIDS or following chemotherapy.
This parameter is also instrumental in the field of transplant immunology, particularly in monitoring the immune reconstitution after bone marrow or stem cell transplants. By evaluating the levels of CD56+CD3- NK cells, clinicians can assess the effectiveness of the transplant and the patient's ability to fight infections and potential relapse of the original disease.
Moreover, the CD56+CD3- % measurement is gaining increasing importance in the development and monitoring of new immunotherapies, especially in the treatment of cancers. These therapies often aim to enhance the activity of NK cells against cancer cells, making the monitoring of CD56+CD3- cells essential for evaluating treatment efficacy.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.